 effect differenti agent hexamethylen bisacetamid normal myelodysplast hematopoiet progenitor hexamethylen bisacetamid hmba nsc potent polar-planar agent leukemia solid tumor cell line vitro achiev concentr hmba patient myelodysplast syndrom previou phase trial hmba hematolog toxic normal bone marrow patient solid tumor concern hmba sever myelotox patient myelodysplast syndrom patient hematopoiet reserv effect hmba myelodysplast normal hematopoiet progenitor vitro hmba concentr optim differenti vitro mmol/l hmba concentr clinic trial mmol/l growth granulocyte-macrophag colony-form unit erythroid burst-form unit patient myelodysplast syndrom normal subject hmba prolifer myelodysplast normal progenitor concentr ident inhibit normal myelodysplast hematopoiet progenitor hmba similar inhibit clonogen leukem growth myeloid leukemia cell line differenti agent effect differenti prolifer abnorm hematopoiet progenitor select inhibitori effect abnorm normal progenitor mechan respons antiprolif effect hmba studi similar inhibitori effect hmba normal abnorm hematopoiet progenitor hmba limit util elev peripher blood cell count patient myelodysplast syndrom